Inicio / Gastroenterología / Abstracts de gastroenterología / Bacterial therapy for irritab…

Bacterial therapy for irritable bowel syndrome

0 / 5 (0 votos)
Bacterial therapy for irritable bowel syndrome

The Lancet Gastroenterology & Hepatology

Fecha de publicación: April 08, 2020

DOI: DOI:https://doi.org/10.1016/S2468-1253(20)30079-0

Autores: Nicholas J Talley, Mudar Irani, Simon Keely

Background: There is increasing evidence that irritable bowel syndrome (IBS) and functional dyspepsia, which often overlap, might have an underlying microbial pathogenesis, leading to intense interest in treatments that modulate the intestinal microbiome. After acute infectious gastroenteritis, typical symptoms of IBS, functional dyspepsia, or both can develop and can persist despite rapid clearance of the acute infection, regardless of the initiating pathogen. Treatment with antibiotics for non-enteric infections is also a risk factor for both IBS and functional dyspepsia, implicating the intestinal microbiome in the underlying pathogenesis. Double hydroxides are good vehicles to improve stability, resistance to degradation of CUR, also they are useful to improve solubility, provide a controlled release and improve the cytotoxic activity. Additionally, it was shown that the composition of the M+2 cation of LDH affects its properties and structure and that this directly influences its biological activity. The findings are important to select the composition of the encapsulation vehicle for a specific activity.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.